EMERYVILLE, Calif., Nov. 4, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, will be presenting at the First Annual LifeTech Capital Miami Medical Investors' Conference, and the Fourth Annual Maxim Group Growth Conference.
The LifeTech conference will be held at the JW Marriott Marquis in Miami, Florida on Friday, November 12. The NovaBay presentation is scheduled for 11:00AM/ET - 11:20AM/ET. Following the presentation, Ron Najafi, Chairman and CEO of NovaBay, will participate in a panel discussion running from 12:30pm - 1:00pm on the topic of "Innovations in Science and Industry." The LifeTech Capital Conference brings together promising biotechnology companies, medical and scientific key opinion leaders with institutional and accredited investors from across the country. For more information on the conference, visit:
The Fourth Annual Maxim Group Growth Conference will be held at the Grand Hyatt, New York, on Thursday, November 18. The NovaBay presentation is scheduled for 3:00PM/ET – 3:30PM/ET, and will be held in the Morosco room in the Biotechnology track. More than 80 domestic and international companies and over 1,000 buy side investors are expected to attend the single-day Maxim Group Growth Conference, which combines company presentations, break-out sessions and management 1-on-1 meetings. For more information on the conference, visit:
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. NovaBay's Aganocide® compounds are being developed to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing hospital and respiratory infections. The company has a license and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds to treat eye, ear and sinus infections as well as for contact lens care. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in impetigo and other dermatological indications. For more information on NovaBay, visit: .
CONTACT: NovaBay Pharmaceuticals, Inc. Investors: Thomas J. Paulson, Chief Financial Officer 510-899-8809 email@example.com The Investor Relations Group Investor Relations Adam Holdsworth 212-825-3210 firstname.lastname@example.org Public Relations Laura Colontrelle 212-825-3210 email@example.com